AR092325A1 - Formulaciones estabilizadas que contienen anticuerpos anti-dll4 y kit - Google Patents
Formulaciones estabilizadas que contienen anticuerpos anti-dll4 y kitInfo
- Publication number
- AR092325A1 AR092325A1 ARP130101868A ARP130101868A AR092325A1 AR 092325 A1 AR092325 A1 AR 092325A1 AR P130101868 A ARP130101868 A AR P130101868A AR P130101868 A ARP130101868 A AR P130101868A AR 092325 A1 AR092325 A1 AR 092325A1
- Authority
- AR
- Argentina
- Prior art keywords
- seq
- kit
- formulations containing
- containing anti
- dll4 antibodies
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
Reivindicación 1: Una formulación farmacéutica que comprende: (i) un anticuerpo que se une específicamente a ligando tipo d humano 4 (Dll4); (ii) un amortiguador a pH de 6,0 ± 0,5; (iii) un cosolvente orgánico; y (iv) dos estabilizadores térmicos. Reivindicación 2: La formulación farmacéutica de acuerdo con la reivindicación 1, en donde el anticuerpo comprende una HCDR1 de SEC ID Nº 2, una HCDR2 de SEC ID Nº 3, una HCDR3 de SEC ID Nº 4, una LCDR1 de SEC ID Nº 6, una LCDR2 de SEC ID Nº 7 y una LCDR3 de SEC ID Nº 8. Reivindicación 3: La formulación farmacéutica de acuerdo con la reivindicación 1 o la reivindicación 2, en donde el anticuerpo comprende una HCVD de SEC ID Nº 1 y una LCVD de SEC ID Nº 5.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261653478P | 2012-05-31 | 2012-05-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR092325A1 true AR092325A1 (es) | 2015-04-15 |
Family
ID=48670784
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130101868A AR092325A1 (es) | 2012-05-31 | 2013-05-29 | Formulaciones estabilizadas que contienen anticuerpos anti-dll4 y kit |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US9675692B2 (es) |
| EP (1) | EP2854849B1 (es) |
| JP (1) | JP6144758B2 (es) |
| KR (1) | KR20150033615A (es) |
| CN (1) | CN104349791A (es) |
| AR (1) | AR092325A1 (es) |
| AU (1) | AU2013267301B2 (es) |
| BR (1) | BR112014028997A2 (es) |
| CA (1) | CA2872275C (es) |
| CL (1) | CL2014003237A1 (es) |
| CO (1) | CO7151478A2 (es) |
| DK (1) | DK2854849T3 (es) |
| EA (1) | EA029779B1 (es) |
| ES (1) | ES2668900T3 (es) |
| HK (1) | HK1207305A1 (es) |
| IL (1) | IL235468A0 (es) |
| LT (1) | LT2854849T (es) |
| MA (1) | MA37645B1 (es) |
| MX (1) | MX357146B (es) |
| NO (1) | NO2887943T3 (es) |
| NZ (1) | NZ702288A (es) |
| PH (1) | PH12014502429B1 (es) |
| PL (1) | PL2854849T3 (es) |
| PT (1) | PT2854849T (es) |
| SG (1) | SG11201407171XA (es) |
| SI (1) | SI2854849T1 (es) |
| TW (1) | TWI609696B (es) |
| UY (1) | UY34842A (es) |
| WO (1) | WO2013181486A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2895226T3 (es) | 2009-10-16 | 2022-02-18 | Mereo Biopharma 5 Inc | Combinación terapéutica y uso de anticuerpos antagonistas de DLL4 y agentes antihipertensivos |
| HUE061002T2 (hu) | 2011-09-23 | 2023-04-28 | Mereo Biopharma 5 Inc | VEGF/DLL4-kötõ ágensek és alkalmazásaik |
| WO2016070051A2 (en) | 2014-10-31 | 2016-05-06 | Oncomed Pharmaceuticals, Inc. | Combination therapy for treatment of disease |
| JP6781508B2 (ja) * | 2014-11-18 | 2020-11-04 | 塩野義製薬株式会社 | 安定化されたペプチド組成物 |
| EP3353204B1 (en) | 2015-09-23 | 2023-10-18 | Mereo BioPharma 5, Inc. | Bi-specific anti-vegf/dll4 antibody for use in treating platinum-resistant ovarian cancer |
| AU2019254473A1 (en) * | 2018-04-16 | 2020-12-03 | Merck Patent Gmbh | Additives for protein formulations to improve thermal stability |
| AU2020225202B2 (en) | 2019-02-18 | 2023-10-26 | Eli Lilly And Company | Therapeutic antibody formulation |
| CN115812080A (zh) * | 2020-07-08 | 2023-03-17 | 瑞泽恩制药公司 | 含有抗ctla-4抗体的稳定调配物 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0747045B2 (ja) | 1986-10-15 | 1995-05-24 | 株式会社大協精工 | 積層した注射器用滑栓 |
| US5016784A (en) | 1990-02-15 | 1991-05-21 | Dexus Research Inc. | Applicator for highly reactive materials |
| WO1993000807A1 (en) | 1991-07-03 | 1993-01-21 | Cryolife, Inc. | Method for stabilization of biomaterials |
| JP3100727B2 (ja) | 1992-01-23 | 2000-10-23 | 株式会社大協精工 | 変性ポリシロキサン組成物及び該組成物を被覆した衛生ゴム製品 |
| EP0652950B1 (en) | 1992-07-24 | 2007-12-19 | Amgen Fremont Inc. | Generation of xenogeneic antibodies |
| JP3172057B2 (ja) | 1995-04-05 | 2001-06-04 | 株式会社大協精工 | ラミネートゴム栓 |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| EP0852951A1 (de) | 1996-11-19 | 1998-07-15 | Roche Diagnostics GmbH | Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern |
| US7312196B2 (en) | 1997-01-08 | 2007-12-25 | Amylin Pharmaceuticals, Inc. | Formulations for amylin agonist peptides |
| WO1998056418A1 (en) | 1997-06-13 | 1998-12-17 | Genentech, Inc. | Stabilized antibody formulation |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| JP3512349B2 (ja) | 1999-01-29 | 2004-03-29 | 株式会社大協精工 | 柱状ゴム要素の成形型 |
| US7001892B1 (en) | 1999-06-11 | 2006-02-21 | Purdue Research Foundation | Pharmaceutical materials and methods for their preparation and use |
| US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
| US6629949B1 (en) | 2000-05-08 | 2003-10-07 | Sterling Medivations, Inc. | Micro infusion drug delivery device |
| US6659982B2 (en) | 2000-05-08 | 2003-12-09 | Sterling Medivations, Inc. | Micro infusion drug delivery device |
| US8632778B2 (en) | 2000-08-11 | 2014-01-21 | Chugai Seiyaku Kabushiki Kaisha | Stabilized anti-interleukin-6 antibody-containing preparations |
| EP1324776B2 (en) | 2000-10-12 | 2018-03-21 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| JP2002209975A (ja) | 2001-01-19 | 2002-07-30 | Daikyo Seiko Ltd | 医薬バイアル用ラミネートゴム栓 |
| WO2003009817A2 (en) | 2001-07-25 | 2003-02-06 | Protein Design Labs, Inc. | Stable lyophilized pharmaceutical formulation of igg antibodies |
| DK1475101T3 (da) | 2002-02-14 | 2011-01-10 | Chugai Pharmaceutical Co Ltd | Antistof-holdige farmaceutiske opløsninger |
| WO2004055164A2 (en) | 2002-12-13 | 2004-07-01 | Abgenix, Inc. | System and method for stabilizing antibodies with histidine |
| LT2335725T (lt) | 2003-04-04 | 2017-01-25 | Genentech, Inc. | Didelės koncentracijos antikūno ir baltymo kompozicijos |
| WO2005072772A1 (en) | 2004-01-30 | 2005-08-11 | Suomen Punainen Risti Veripalvelu | Pharmaceutical compositions |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| WO2006104852A2 (en) | 2005-03-25 | 2006-10-05 | Regeneron Pharmaceuticals, Inc. | Vegf antagonist formulations |
| WO2006138181A2 (en) | 2005-06-14 | 2006-12-28 | Amgen Inc. | Self-buffering protein formulations |
| MX2008016124A (es) | 2006-06-16 | 2009-01-20 | Regeneron Pharma | Formulaciones antagonistas de vegf adecuadas para la administracion intravitreal. |
| JP2010507624A (ja) | 2006-10-27 | 2010-03-11 | アブリンクス エン．ヴェー． | ポリペプチド及びタンパク質の鼻内送達 |
| RU2448979C2 (ru) | 2006-12-14 | 2012-04-27 | Ридженерон Фармасьютикалз, Инк. | Антитела человека к дельта-подобному лиганду-4 человека |
| CN102414221A (zh) | 2009-03-06 | 2012-04-11 | 健泰科生物技术公司 | 抗体配制剂 |
| ES2895226T3 (es) * | 2009-10-16 | 2022-02-18 | Mereo Biopharma 5 Inc | Combinación terapéutica y uso de anticuerpos antagonistas de DLL4 y agentes antihipertensivos |
| PT3721904T (pt) | 2009-11-20 | 2021-11-15 | Biocon Ltd | Formulações de anticorpo t1h |
| RU2016146198A (ru) | 2010-03-02 | 2018-12-19 | Эббви Инк. | Терапевтические dll4-связывающие белки |
| CA2813587C (en) * | 2010-10-06 | 2019-01-15 | Regeneron Pharmaceuticals, Inc. | Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies |
-
2013
- 2013-05-29 AR ARP130101868A patent/AR092325A1/es unknown
- 2013-05-30 TW TW102119047A patent/TWI609696B/zh not_active IP Right Cessation
- 2013-05-31 WO PCT/US2013/043516 patent/WO2013181486A1/en active Application Filing
- 2013-05-31 SG SG11201407171XA patent/SG11201407171XA/en unknown
- 2013-05-31 MA MA37645A patent/MA37645B1/fr unknown
- 2013-05-31 PT PT137307021T patent/PT2854849T/pt unknown
- 2013-05-31 NZ NZ702288A patent/NZ702288A/en not_active IP Right Cessation
- 2013-05-31 DK DK13730702.1T patent/DK2854849T3/en active
- 2013-05-31 PL PL13730702T patent/PL2854849T3/pl unknown
- 2013-05-31 CN CN201380028578.1A patent/CN104349791A/zh active Pending
- 2013-05-31 AU AU2013267301A patent/AU2013267301B2/en active Active
- 2013-05-31 UY UY0001034842A patent/UY34842A/es unknown
- 2013-05-31 US US13/906,479 patent/US9675692B2/en active Active
- 2013-05-31 EP EP13730702.1A patent/EP2854849B1/en active Active
- 2013-05-31 EA EA201492186A patent/EA029779B1/ru not_active IP Right Cessation
- 2013-05-31 CA CA2872275A patent/CA2872275C/en active Active
- 2013-05-31 BR BR112014028997A patent/BR112014028997A2/pt not_active IP Right Cessation
- 2013-05-31 MX MX2014014363A patent/MX357146B/es active IP Right Grant
- 2013-05-31 KR KR1020147035879A patent/KR20150033615A/ko not_active Application Discontinuation
- 2013-05-31 SI SI201330979T patent/SI2854849T1/en unknown
- 2013-05-31 LT LTEP13730702.1T patent/LT2854849T/lt unknown
- 2013-05-31 JP JP2015515218A patent/JP6144758B2/ja active Active
- 2013-05-31 ES ES13730702.1T patent/ES2668900T3/es active Active
- 2013-08-23 NO NO13831626A patent/NO2887943T3/no unknown
-
2014
- 2014-10-29 PH PH12014502429A patent/PH12014502429B1/en unknown
- 2014-11-03 IL IL235468A patent/IL235468A0/en unknown
- 2014-11-27 CL CL2014003237A patent/CL2014003237A1/es unknown
- 2014-12-23 CO CO14281503A patent/CO7151478A2/es unknown
-
2015
- 2015-08-18 HK HK15108004.0A patent/HK1207305A1/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR092325A1 (es) | Formulaciones estabilizadas que contienen anticuerpos anti-dll4 y kit | |
| PE20181921A1 (es) | NUEVOS ANTICUERPOS ANTI-SIRPa Y SUS APLICACIONES TERAPEUTICAS | |
| NZ630885A (en) | Antibody formulation | |
| PE20141151A1 (es) | Proteinas de union al antigeno cd27l | |
| CO6230999A2 (es) | Anticuerpo anti-esclerostina | |
| PE20170903A1 (es) | Conjugados de farmacos con anticuerpos anti-cdh6 | |
| PE20130226A1 (es) | Anticuerpos hacia gdf8 humano | |
| PE20130817A1 (es) | Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos | |
| PE20181326A1 (es) | Anticuerpos que se unen especificamente a pd-1 y sus usos | |
| PE20181090A1 (es) | Modulacion y tratamiento inmunes de tumores solidos con anticuerpos que se unen especificamente a cd38 | |
| AR110203A1 (es) | Anticuerpos anti-tim-3 para combinación con anticuerpos anti-pd-1 | |
| NZ627859A (en) | Stabilized formulations containing anti-ang2 antibodies | |
| AR110017A1 (es) | Anticuerpos de pd-1 y usos de estos | |
| NZ731735A (en) | Anti-pd-1 antibodies and methods of use thereof | |
| AR071891A1 (es) | Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano) | |
| HRP20171964T1 (hr) | Kombinacije i njihova upotreba | |
| PE20091261A1 (es) | Anticuerpos anti-hepcidina | |
| NZ719036A (en) | Anti-pdl1 antibody formulations | |
| PE20170916A1 (es) | Composiciones y metodos para anticuerpos dirigidos a bmp6 | |
| NZ740221A (en) | St2l antagonists and methods of use | |
| NZ729158A (en) | Anti-ctla4 monoclonal antibody or antigen binding fragment thereof, medicinal composition and use | |
| PE20150159A1 (es) | Composiciones y metodos para anticuerpos que actuan sobre el factor p | |
| AR081434A1 (es) | Anticuerpo del peptido relacionado con el gen calcitonina (cgrp), composicion farmaceutica que lo comprende, uso de dicho anticuerpo para preparar un medicamento util para tratar dolor de osteoartritis o migranas y fragmento de union a antigeno de dicho anticuerpo | |
| PE20141706A1 (es) | Anticuerpos de union a trombina y usos del mismo | |
| PE20141147A1 (es) | Anticuerpos a pcsk9 y usos de los mismos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |